Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 2,627 | 348 | 2,270 |
| Samples | 832 | 159 | 670 |
| Peptides | 694 | 119 | 591 |
Function
TRPM1 · Transient receptor potential cation channel subfamily M member 1
This gene encodes a member of the transient receptor potential melastatin subfamily of transient receptor potential ion channels. The encoded protein is a calcium permeable cation channel that is expressed in melanocytes and may play a role in melanin synthesis. Specific mutations in this gene are the cause autosomal recessive complete congenital stationary night blindness-1C. The expression of this protein is inversely correlated with melanoma aggressiveness and as such it is used as a prognostic marker for melanoma metastasis. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2011].
Isoforms & Proteins
4 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 667 amino-acid changes on canonical ENST00000256552 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in TRPM1 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in TRPM1 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Cell Non-Hodgkins Lymphoma | 3/26 12% | 0/0 0% |
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Endometrial Carcinoma | 11/42 26% | 40/612 7% |
| Non-Small Cell Lung Carcinoma | 20/304 7% | 61/1390 4% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Chronic Myelogenous Leukemia | 1/25 4% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 5/57 9% | 29/810 4% |
| Acute Monocytic Leukemia | 0/1 0% | 1/25 4% |
| Melanoma | 15/210 7% | 66/1899 3% |
| Oral Cavity Carcinoma | 2/54 4% | 0/0 0% |
| Other Solid Cancers | 1/94 1% | 53/1515 4% |
| Cervical Carcinoma | 1/35 3% | 14/422 3% |
| Colorectal Carcinoma | 20/143 14% | 75/3239 2% |
| Unknown | 0/10 0% | 1/29 3% |
| Neuroendocrine Tumour | 10/154 6% | 8/577 1% |
| Gastric Carcinoma | 4/74 5% | 40/1809 2% |
| Hodgkins Lymphoma | 2/16 12% | 1/122 1% |
| Bladder Carcinoma | 4/58 7% | 17/956 2% |
| Non-Cancerous | 4/104 4% | 12/830 1% |
| Other Sarcomas | 4/69 6% | 9/699 1% |
| Meningioma | 0/3 0% | 4/252 2% |
| Ovarian Carcinoma | 3/109 3% | 13/998 1% |
| Plasma Cell Myeloma | 3/44 7% | 2/305 1% |
| Esophageal Squamous Cell Carcinoma | 4/51 8% | 32/2550 1% |
| Head and Neck Carcinoma | 1/85 1% | 19/1574 1% |
| Biliary Tract Carcinoma | 1/54 2% | 11/950 1% |
| Esophageal Carcinoma | 1/23 4% | 8/769 1% |
| Breast Carcinoma | 8/144 6% | 29/3264 1% |
| Rhabdomyosarcoma | 0/33 0% | 2/171 1% |
| Glioma | 2/52 4% | 19/2127 1% |
Mutation Distribution
Where TRPM1 is mutated · all tissues, split by cell line vs tissue
How many mutations in TRPM1 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 42 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 2,627 mutations in TRPM1
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|